Evidence map›Paper›PMID 32694239›Full record

ArticleAging2020

Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.

Shengzhong Hou, Xing Chen, Mao Li, Xing Huang, Haotian Liao, Bole Tian

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Shengzhong HouDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xing ChenDepartment of Liver Surgery and Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
Mao LiDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xing HuangDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Haotian LiaoDepartment of Liver Surgery and Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
Bole TianDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
West China Hospital of Sichuan University · CNState Key Laboratory of BiotherapySichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The upregulation of cell division cycle associated protein 5 (CDCA5) has been observed in various cancer types. However, the prognostic value of CDCA5 and its underlying mechanism contributing to tumorigenesis in hepatocellular carcinoma (HCC) remain poorly understood. We used tissue microarray (TMA) to evaluate the prognosis of 304 HCC samples based on their CDCA5 expression, and analyzed the genomic features correlated with CDCA5 by using dataset from The Cancer Genome Atlas (TCGA). Compared with adjacent normal tissues, increased expression of CDCA5 was found in HCC tissues. Moreover, higher expression of CDCA5 was associated with inferior OS and DFS outcomes in HCC patients. The enrichment plots showed that the gene signatures in cell cycle, DNA replication and p53 pathways were enriched in patients with higher CDCA5 expression. Meanwhile, statistically higher mutations burdens in TP53 could also be observed in CDCA5-high patients. Integrative analysis based on miRNAseq and methylation data demonstrated a potential association between CDCA5 expression and epigenetic changes. In conclusion, our study provided the evidence of CDCA5 as an oncogenic promoter in HCC and the potential function of CDCA5 in affecting tumor microenvironment.

Indexed as

Adaptor Proteins, Signal TransducingCarcinoma, HepatocellularCell Cycle ProteinsDisease-Free SurvivalEpigenesis, GeneticGene Expression Regulation, NeoplasticGenes, p53HumansLiver NeoplasmsMutationPredictive Value of TestsPrognosisSurvival AnalysisTumor MicroenvironmentTumor Suppressor Protein p53Adaptor Proteins, Signal TransducingCDCA5 protein, humanCell Cycle ProteinsTP53 protein, humanTumor Suppressor Protein p53bioinformaticscell division cycle-associated protein 5hepatocellular carcinomaprognosis

Identifiers

PMID32694239
PMCPMC7425481
OpenAlexW3044589583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.